Clinical trials: Exposure, Environmental
Smoking, Tobacco, Smoking
GeoScan and Remote Geo Smoking Study: Neural and Behavioral Correlates of Smokers' Exposure to Retail Environments
The purpose of the study is to learn more about the relationships between the brain, behavior, and natural daily exposure to particular environments, including the places where smokers regularly spend time and specific retail…
- Conditions
- Smoking, Tobacco, Smoking, Smoking, Cigarette
- Trial name
- NCT04279483
- Testing
- Tobacco retailer, Non-tobacco retailer
- Where
- United States
- Volunteers
- 343 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Environmental Exposure, Nasal Inflammation
Human Biological Responses to Low Level Ozone
To investigate if low level ozone exposure will cause measurable inflammation in nasal cells.
- Trial name
- SNOZ (NCT02857283)
- Testing
- Ozone, Filtered Air, Health and Exposure Tracker (HET)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Allergic Rhinitis
An Efficacy Study of JNJ-39220675 and Pseudoephedrine in Participants With Allergic Rhinitis
The purpose of this study is to evaluate the relative efficacy of JNJ- 39220675 and pseudoephedrine compared to placebo (medication with no active ingredients) in participants with allergic rhinitis (inflammation of the nose due…
- Trial name
- NCT00804687
- Testing
- JNJ-39220675, Pseudoephedrine
- Where
- Canada
- Volunteers
- 53 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Seasonal Allergic Rhinitis
Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber
The purpose of this study is to examine the safety and efficacy of bepotastine besilate nasal product in seasonal allergic rhinitis patients.
- Trial name
- NCT01222299
- Testing
- bepotastine besilate nasal product - low dose, bepotastine besilate nasal product - medium dose, bepotastine besilate nasal product - high dose
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Bausch & Lomb Incorporated
Conjunctivitis, Allergic
A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber
An Exploratory Clinical Trial Evaluating Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)
- Trial name
- NCT03709121
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Endocrine Disrupting Chemicals, Environmental Exposure
Personalized Mobile Intervention to Reduce Exposure to Endocrine Disrupting Chemicals in Adults of Child-Bearing Age
The goal of this intervention study is to determine to what extent the Million Marker (MM) program reduces users' endocrine disruption chemical (EDC) exposure levels and changes their environmental health awareness and behaviors.
- Conditions
- Endocrine Disrupting Chemicals, Environmental Exposure, Health Literacy, Bisphenol A
- Trial name
- NCT05780047
- Testing
- Mail-in Urine Test for EDCs
- Where
- United States
- Volunteers
- 434 people, healthy volunteers welcome
- Sponsor
- Million Marker Wellness, Inc.
Asthma, Environmental Exposure
Home Air Quality Impact for Adults With Asthma
The purposes of this study are to determine the practicality of using home indoor air quality monitoring and a smartphone app to identify home air quality changes and how these changes affect adults with asthma.
- Conditions
- Asthma, Environmental Exposure, Home Environment Related Disease
- Trial name
- NCT05224076
- Testing
- Home Air Quality
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of Kansas Medical Center
Pulmonary Disease, Chronic Obstructive
Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the Drug
This single and repeat increasing dose study will collect information on safety, tolerability and drug levels in the body of the CCI15106 inhalation powder.
- Trial name
- NCT03235726
- Testing
- CCI15106
- Where
- United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rhinitis, Allergic
A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen
The purpose of the study is to assess the efficacy comparability of cetirizine and levocetirizine, by comparing the effects of single intake of the two drugs to placebo in reducing symptoms of seasonal allergic rhinitis (SAR) in…
- Conditions
- Rhinitis, Allergic, Seasonal
- Trial name
- NCT00291642
- Testing
- Levocetirizine drops, Levocetirizine tablets
- Where
- Canada
- Volunteers
- 551 people
- Sponsor
- UCB Pharma
Allergic Conjunctivitis
Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis
The purpose of this study is to evaluate two investigational ophthalmic solutions for reduction in ocular redness in subjects with allergic conjunctivitis.
- Trial name
- NCT02079649
- Testing
- AL-53817 Ophthalmic Solution, 0.1%, AL-78843 Ophthalmic Solution, 0.03%, Dexamethasone Ophthalmic Suspension, 0.1%
- Volunteers
- 224 people
- Sponsor
- Alcon Research
Rhinitis, Allergic, Seasonal
Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects
To compare the clinical efficacy of levocetirizine 5 mg and montelukast 10 mg on symptoms of seasonal allergic rhinitis occurring in subjects exposed to ragweed pollen in an environmental exposure unit.
- Trial name
- NCT00295022
- Testing
- Montelukast, Levocetirizine
- Where
- Canada
- Volunteers
- 418 people
- Sponsor
- UCB S.A. - Pharma Sector
Iraq and Afghanistan Era Veterans
Service and Health During the Iraq and Afghanistan Era
The primary objective of CSP #595, "Service and Health During the Iraq and Afghanistan Era," is to characterize the impact of deployment to Iraq and Afghanistan on the respiratory health of Veterans.
- Trial name
- CSP #595 Pilot (NCT01987401)
- Where
- 2 sites in United States
- Volunteers
- 1,242 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Environmental Exposure
Benzo[a]Pyrene Ultralow Dose-Response Study
Evaluation of the pharmacokinetics for [14C]-benzo[a]pyrene ([14C]-BaP) and metabolites in plasma and urine over 48 hours following 4 oral doses of 25, 50, 10 and 250 ng (2.7-27 nCi).
- Trial name
- NCT03318978
- Testing
- [14C]-benzo[a]pyrene
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Oregon State University
Dry Eye Syndromes
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
This study evaluates the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally (active) compared with the same device applied extranasally (control) relating to symptoms of dry eye exacerbated by…
- Trial name
- NCT02910713
- Testing
- Intranasal Tear Neurostimulator
- Where
- 3 sites in United States
- Volunteers
- 185 people
- Sponsor
- Allergan
Environmental Exposure
Real-Life Passive Exposure Assessment of IQOS
This study is a non-interventional observational study designed to assess the impact of passive exposure to IQOS environmental tobacco aerosol in Non-Smokers in a real-life restaurant setting.
- Trial name
- NCT03550989
- Testing
- Non-Exposure Event, Exposure Event
- Where
- Japan
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Nasal Allergies, Allergies
Safety and Efficacy of AL-53817 Nasal Spray Solution
The purpose of this study was to determine the maximum tolerated dose of AL-53817 (Stage A) and evaluate the safety and efficacy of AL-53817 for the treatment of allergic rhinitis (Stage B).
- Trial name
- NCT01454505
- Testing
- AL-53817 nasal spray solution, Vehicle nasal spray
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)
The purpose of this study is to evaluate the dose-related effectiveness, the safety and the tolerability of MK-8237, compared to placebo, in the treatment of house dust mite (HDM)-induced allergic rhinitis/rhinoconjunctivitis in…
- Trial name
- NCT01644617
- Testing
- MK-8237 6 DU, MK-8237 12 DU
- Volunteers
- 124 people
- Sponsor
- ALK-Abelló A/S
Environmental Exposure
Ultralow Dose PAH Binary Mixture Study
Evaluation of the pharmacokinetics for [14C]-benzo[a]pyrene ([14C]-BaP) and metabolites in plasma and urine over 48 hours following a 50 ng dose (5.4 nCi) alone or with 1250 ng phenanthrene.
- Trial name
- NCT03631667
- Testing
- [14C]-benzo[a]pyrene, [14C]-benzo[a]pyrene plus phenanthrene
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Oregon State University
Dry Eye Syndromes
Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye
The purpose of this study was to evaluate the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally compared with the same device applied extranasally (control) in treating the symptoms of dry eye…
- Trial name
- NCT02313454
- Testing
- Intranasal Tear Neurostimulator
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Allergan
Allergic Conjunctivitis
The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis
The INVIGORATE 2 Trial: A single-center, randomized, double-masked, crossover design, vehicle-controlled, Phase 3 clinical trial to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared to vehicle in…
- Trial name
- NCT05234554
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 131 people
- Sponsor
- Aldeyra Therapeutics, Inc.